The application relates to an formulation for anti-[alpha]4[beta]7 antibody. The invention describes antibody formulation comprising a mixture of an anti-alpha]4[beta]7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulation may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of the antibody formulation that is easy to follow, and which results in a therapeutically effective amount of the anti-[alpha]4[beta]7 in vivo.